UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000010035 |
|---|---|
| Receipt number | R000011730 |
| Scientific Title | The effect of prostaglandin I2 analogue on diabetic nephropathy in diabetic patients with peripheral arterial disease |
| Date of disclosure of the study information | 2013/02/19 |
| Last modified on | 2015/07/09 00:22:17 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
The effect of prostaglandin I2 analogue on diabetic nephropathy in diabetic patients with peripheral arterial disease
Acronym
The effect of prostaglandin I2 analogue on diabetic nephropathy in diabetic patients with peripheral arterial disease
Scientific Title
The effect of prostaglandin I2 analogue on diabetic nephropathy in diabetic patients with peripheral arterial disease
Scientific Title:Acronym
The effect of prostaglandin I2 analogue on diabetic nephropathy in diabetic patients with peripheral arterial disease
Region
| Japan |
Condition
Condition
Diabetic nephropathy
Classification by specialty
| Medicine in general | Cardiology | Endocrinology and Metabolism |
| Nephrology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
The effect of prostaglandin I2 analogue on diabetic nephropathy in diabetic patients with peripheral arterial disease
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Creatinine, eGFR, cystatin C
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Blinding
Open -but assessor(s) are blinded
Control
Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Oral beraprost sodium administration (60 µg) third daily.
Interventions/Control_2
standard therapy
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1) Age more than 20 years
2) Outpatients
3) Diabetic nephropathy in patients with peripheral arterial disease
4) Serum Creatinine<2.0mg/dl
5) Patients who themselves can voluntarily provide written consent to participate in this study, and can also follow the study protocol
Key exclusion criteria
1) Previous administration of pioglitazone or DPP-4 inhibitor as an oral hypoglycemic drug
2) 8.0% more than fasting HbA1c
3) Patients with proliferative diabetic retinopathy
4) Patients with bleeding tendency
5) Severe hepatopathy/nephropathy or heart disease that may affect the evaluation of drug safety
6) Patients who are deemed to be inappropriate by the investigator or sub-investigators
Target sample size
40
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Kyoichi Mizuno |
Organization
Nippon Medical School Department of Medicine
Division name
Division of Cardiology
Zip code
Address
1-1-5, Sendagi, Bunkyo-ku, Tokyo Japan 113-8603
TEL
03-3822-2131
ykubota@nms.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Ayaka Shima |
Organization
Nippon Medical School Department of Medicine
Division name
Division of Cardiology
Zip code
Address
1-1-5, Sendagi, Bunkyo-ku, Tokyo Japan 113-8603
TEL
03-3822-2131
Homepage URL
ykubota@nms.ac.jp
Sponsor or person
Institute
Nippon Medical School Department of Medicine
Division of Cardiology
Institute
Department
Personal name
Funding Source
Organization
Nippon Medical School Department of Medicine
Division of Cardiology
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2013 | Year | 02 | Month | 19 | Day |
Related information
URL releasing protocol
Publication of results
Published
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2012 | Year | 04 | Month | 01 | Day |
Date of IRB
Anticipated trial start date
| 2013 | Year | 02 | Month | 19 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2013 | Year | 02 | Month | 14 | Day |
Last modified on
| 2015 | Year | 07 | Month | 09 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011730
